基本信息
浏览量:49
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
Medical oncologist;
Head of the Gynecological and Genitourinary Cancer and Melanoma Unit.
Director of the Rare Tumors Programmes
Centro Integral Oncologico Clara Campal
Madrid
Biosketch: Jesús García-Donas
Jesus Garcia-Donas was born in Alcalá de Guadaira (Sevilla) in 1974. He received his MD from the Universidad Complutense de Madrid in 1998 and subsequently trained as Medical Oncologist at the Hospital Universitario Clinico San Carlos, Madrid. After completing his oncology training in 2002, Jesus worked first in the Hospital Universitario de Elche. In 2003 later Jesus joined the Oncology Department of the Hospital Universitario Fundación Alcorcon, focusing in hereditary cancer syndroms and genitourinary tumors. In 2009, He completed his sub-specialization in Genitourinary Tumours with a Astra-Zeneca fellowship at the New York Langone Medical Center under the supervision of Dr. Ana Ferrari. Since May 2012 Jesus leads the Genitourinary Tumors and Rare Cancer Programme at the Centro Integral Oncológico Clara Campal (Madrid).
Jesus has participated as co-investigator in up to 130 Phase I, II and III clinical trials and has published over 20 papers in peer-reviewed journals, including the prestigious The Lancet Oncology and Journal of Clinical Oncology.
Jesus currently leads several translational projects and clinical trials in the field of Kidney Cancer and Rare Tumors. Most relevant are the EuroTarget study funded by the 7th Framework Program of the European Union, that will deeply improve our knowledge of predictive biomarkers in renal tumors, the CIRClEs study (Circulating Endothelial Cells in renal cancer) and the phase II study of dovitnib, a new tyrosin kinase inhibitor, in adrenocortical carcinomas.
He has also designed and currently leads the Genedrivity (GENEtically DRIVen TrYal) Project, a pan-European study that accounts with the commitment of 8 different national collaborative groups. This study will prospectively evaluate for first time the influence of the genetic background of patients in response to targeted therapies in kidney cáncer.
Jesus has also received several grants and awards including the 2006 FREMAP award for investigational projects, the “Fundación Renal Iñigo Alvarez de Toledo” award and a grant for Independent Clinical Investigation from the Health Spanish Ministry (EC11-178).
研究兴趣
论文共 197 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Sandra Amarilla-Quintana, Paloma Navarro, Alejandra Ramos, Ana Montero-Calle, Pablo Cabezas-Sainz, Maria J Barrero, Diego Megias, Borja Vilaplana-Marti,Carolina Epifano, Deborah Gomez-Dominguez, Ivan Hernandez, Sara Monzon,
biorxiv(2024)
Jordi Rodon,Silvia Damian,Muhammad Furqan,Jesus Garcia-Donas,Hiroo Imai,Antoine Italiano,Iben Spanggaard,Makoto Ueno,Tomoya Yokota, Maria Luisa Veronese,Natalia Oliveira, Xin Li,
NATURE MEDICINEpp.1-10, (2024)
Miguel Quiralte,Arantzazu Barquín, Mónica Yagüe-Fernández,Paloma Navarro, Tatiana P Grazioso,Elena Sevillano-Fernández, Juan F Rodriguez-Moreno, Alejandra Balarezo-Saldivar,Héctor Peinado,Elena Izquierdo, Carlos Millán, Irene López-Carrasco,
The Journal of clinical investigationno. 10 (2024)
Rahul Aggarwal,Antoine Italiano,Susan Domchek,Oscar Goodman,Sophie Postel-Vinay,Jesus Garcia-Donas,Tanya Dorff, Zachery Reichert,Philippe Cassier,Neal Shore, Catherine Marshall,Graeme Parr,
Cancer Researchno. 7_Supplement (2024)
JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023)
引用0浏览0引用
0
0
Jordi Rodon,Silvia Damian,Muhammad Furqan,Jesus Garcia-Donas, Hiroo Imai,Antoine Italiano, Iben Spanggaard,Makoto Ueno,Tomoya Yokota, Luisa Veronese,Natalia Oliveira, Xin Li,
CANCER RESEARCHno. 8 (2023)
引用0浏览0引用
0
0
Jordi Rodon, Silvia Damian, Muhammad Furqan,Jesus Garcia-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno,Tomoya Yokota, Luisa Veronese, Natalia Oliveira, Xin Li,
Cancer Researchno. 8_Supplement (2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn